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Abstract
Background: High-throughput screening of pharmaceutical compound activity in tissue culture
experiments requires time-consuming repeated analysis of the large amounts of data generated.
Automation of the evaluation procedure and assessment of measurement accuracy can save time
and improve the comparability of results.
Results: We present a tool for simultaneous evaluation of an arbitrary number of compound
screens including a standardized statistical validation. It is provided as a novel R package with a Tcl/
Tk-based GUI for convenient use in the lab and runs on usual platforms like Linux, Windows and
Mac OS. In a compound screen of lung cancer cells, the tool was successfully and efficiently applied
for data analysis.
Conclusion: The package provides an efficient and intuitive platform for automatic evaluation of
compound screens, improving the performance and standardization of data analysis.
Background
Cell-based screening of the cytotoxic activity of chemical
compounds in cancer cells has emerged as a widely used
method in the drug discovery process. Typically, cells are
treated with several concentrations of compound in 96- or
384-well microtiter plates for a predefined time period. A
common method to evaluate these experiments in a quan-
titative fashion is to determine a half-maximal inhibitory
concentration (IC50) for which cell growth is inhibited by
50%. Comprehensive efforts have been focused on
screening experiments with thousands of compounds in
industrial laboratories as well as institutions of public
health. A screen of 60 cancer cell lines with a large library
of agents was supervised by the National Cancer Institute
[1]. Yet, these compound screens lack a standardized tool
and implementation for automatic high-throughput eval-
uation. We propose the methods and software applied for
evaluation in a screen of non-small cell lung cancer
(NSCLC) in vitro cell cultures as a standard for cell line
screens in future. The implementation is available for
download under the General Publice License (GPL).
Implementation
Evaluation and validation of compound screens
For l = 1, ..., k, consider the screen of the lth compound in
log-transformed concentrations Xlj with j = 1, ..., ml. On
the other hand, denote by Ylij the observed proportion of
cells still being alive under concentration j in the ith rep-
licate where i = 1, ..., nl. This determines nl dose-response
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curves formed by the respective points (Xl1, ..., Yli1), ...,
(Xlm, ..., Ylim). One IC50 value can be determined from
each of these by the preimage cli of the 50% point under a
linear spline. In real experiments, this value may not be
uniquely determined as the curve crosses the 50% point
several times. In these cases, it is most appropriate to
define the IC50 value as the smallest concentration where
this occurs. The resulting IC50 from the repeated screen is
determined as the mean   of these nl concentrations with
a 95% confidence interval
making use of the fact that the IC50 concentrations are
normally distributed through the above logarithmic trans-
formation which is inverted subsequently after analysis.
Here,   denotes the standard deviation of the nl values. If
most samples are resistant towards a particular compound
in the overall screen, we propose to determine the 25%
inhibitory concentration (IC25 value) instead to get a
more widespread profile for that sample. To guess the
accuracy of an experiment, one point of interest is the var-
iability of the resulting IC50 values. This can be deter-
mined by the coefficient of variation   of these. On the
other hand, the standard deviations of the raw data 
can be determined for each concentration to verify the ini-
tial validity of the measurements. As this results in a total
of  ml values, it is reasonable to regard the maximum
 of these values as the overall accu-
racy of the data points.
Features of the R package
The novel add-on package 'ic50' is available for download
from the Comprehensive R Archive Network (CRAN) and
provides automatic performance of the above evaluation
methods. The functions of the package are appropriate for
immediate use on the R console but can be accessed by an
intuitive GUI as well (Figure 1). The main feature that
makes the described tool exceedingly useful for practice is
that all data in an arbitrary directory on the local harddisk
can be evaluated simultaneously by just one mouse click.
In particular, the amount of data to be evaluated is not
limited and may comprise screens of hundreds or thou-
sands of compounds or samples, respectively, as long as
the same design is shared by all experiments.
Microtiter plates with 96 or 384 wells are supported up to
now. Raw data are expected to be passed as tab-delimited
text files which are the typical output from appropriate
microplate readers. The arrangement of the measurements
on the well matrix can be different for each experimental
setup. To address this, the design can be configured by
three separate files, one specifying the coordinates of the
wells for the actual compound measurements, one for the
locations of control measurements to be used for normal-
ization and a third for specification of the respective con-
centrations used for each measurement. Several samples
of such files are distributed together with the package.
Normalization with control wells can be performed by
taking the mean of a specified control row or by one single
control well per concentration, where wells can be used
multiple times in both cases. Inhibitory percentages can
be configured as 50% for all compounds, which is default,
or any other individual value, e.g. to calculate IC25 values.
Graphical output can be modified by additional options.
As for any R package, there is detailed documentation of
all features available with additional examples for illustra-
tion and a step-by-step tutorial document guiding the user
to prepare his data and configuration files for analysis
with the tool (Additional file 1).
Results and Discussion
Results from an evaluation of the lung cancer cell line
H3255 under treatment with 7 different compounds are
given in Table 1 with the corresponding dose-response
curves for gefitinib and SU11274 in Figure 2. The meas-
urements were carried out using a Mithras LB 940 multi-
mode reader (Berthold Technologies, Bad Wildbad,
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Main window of the GUI-controlled package Figure 1
Main window of the GUI-controlled package. Screen-
shot of the main window of the GUI-controlled 'ic50' pack-
age. Features for specification of the experimental design are 
provided as well as options for evaluation. The use of the 
wells on the plates can be modified by specification of three 
previously created configuration files.BMC Bioinformatics 2008, 9:475 http://www.biomedcentral.com/1471-2105/9/475
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Germany) with the output files converted to tab-delimited
text files before the procedure. In general, the numeric
results are all given in one single text file with the structure
of Table 1 and a graphics output as exemplified in Figure
2 is written to one single pdf file in the specified output
directory for all compounds in the screen. The cell line
H3255 carries an activating mutation of the EGFR gene
making it sensitive to the EGFR inhibitors gefitinib and
erlotinib [2]. The full data collection of this compound
screen will be published elsewhere [3].
For a resistant sample, a typical curve looks like Figure 2b
with no remarkable variation of viability over the concen-
trations. For the IC50 concentration, the tool returns a NA
value in this case and does not include it into the plot. The
same happens if the viability is almost constant at a some-
what lower percentage (Additional file 2, figure (a) and
(b)). However, other kinds of unexpected behaviour may
occur in real experiments. The curve can be non-monot-
onic and cross the 50% point several times (Additional
file 2, figure (c)). As mentioned above, the smallest of the
several concentrations is returned in this case. On the
other hand, erroneous measurements may yield a monot-
onically increasing curve with viability below 50% even
for small concentrations (Additional file 2, figure (d)). In
this case, the tool returns a NA value for the IC50 concen-
tration.
The lowest IC50 value in the H3255 cells was observed
under gefitinib treatment, thus confirming the appropri-
ateness of our screening and analytical approaches [2]. For
the coefficient of variation, a usual standard is to require v
< 0.05 for reasonable accuracy. Regarding the results in
Table 1, the maximum standard deviation ranges between
0.0815 and 0.2413, suggesting an upper threshold of τ =
0.2 for validation. The measurements for rapamycin show
very strong variability with an artificially wide confidence
interval. For the cell line screen, this result was therefore
discarded and replaced by a repeated experiment.
Conclusion
In summary, the 'ic50' package provides a platform for
time-efficient evaluation of cell-based compound screens.
Dose-response curves for H3255 cells under gefitinib and SU11274 treatment Figure 2
Dose-response curves for H3255 cells under gefitinib and SU11274 treatment. Graphical output for the H3255 
NSCLC cell line treated (a) with gefitinib and (b) with SU11274. For gefitinib, the solid line denotes the IC50 value of the 
screen, whereas the 95% confidence bounds are given as dashed lines. These lines are not plotted for SU11274 as the sample is 
resistant to this treatment and there is no well-defined IC50 value. For each concentration, the standard deviation of the meas-
urements is displayed as an error bar.
Table 1: Results for H3255 cells under gefitinib treatment
Compound IC50 clow cup v
17AAG 0.0275 0.0237 0.0321 0.0901 0.0304
Gefitinib 0.0059 0.005 0.007 0.0858 0.0242
Purvalanol 5.689 3.850 8.406 0.1437 0.1618
Rapamycin 5.957 0.0267 1328 0.0815 2.183
SU11274 NA NA NA 0.2413 NA
UO126 8.414 7.218 9.808 0.1727 0.0518
VX680 2.692 0.9192 7.881 0.1226 0.7816
Results of the dose-response experiment for the EGFR-mutant 
H3255 NSCLC cell line treated with small molecule compounds 
17AAG, purvalanol, SU11274, gefitinib, rapamycin, VX680 and U0126. 
The lowest IC50 value (first column) reveals strong activity of 
gefitinib, whereas the NA values indicate that the sample is resistant 
to SU11274 treatment and no IC50 value was calculated. The 
columns clow and cup show the 95% confidence interval for the IC50 
values. The maximum of the standard deviations of the measurements 
is given in the column  , whereas in the last column, v denotes 
the coefficient of variation of the IC50 values.
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The experimental setup can be configured in any order
and re-used for multiple subsequent analyses. A standard-
ized validation is included in the tool and can be used to
assess the accuracy of the experiments. The approach is
suitable to confirm biological activity of targeted drugs in
cancer cells with specific genetic lesions.
Availability and requirements
The 'ic50' package is a platform-independent add-on to
the R environment for statistical computing. It uses a Tcl/
Tk-based GUI and is available at the URL http://cran.r-
project.org/web/packages/ic50/index.html under the
General Public License (GPL). There are no restrictions for
its use. An installation of the R environment with Tcl/Tk
support is required. The package is also available as addi-
tional material to this paper (Additional files 3 and 4).
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Additional file 1
Tutorial. This document aims to help the user getting started with the 
package: the correct formatting of the input data and configuration files is 
explained in a step-by-step manual.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-475-S1.pdf]
Additional file 2
Supplementary Figure. This figure displays several situations with typical 
exceptions occuring in the measurements: (a) cell viability is essentially 
constant at 50%, (b) cell viability is essentially constant at 0%, (c) the 
curve crosses the 50% point several times, and (d) the percentage is 
monotonically increasing for increasing concentrations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-475-S2.jpeg]
Additional file 3
Source code of the software. The platform-independent source code for 
version 1.3 of the package is provided as a gzipped tar archive.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-475-S3.tar.gz]
Additional file 4
Windows binary code of the software. A pre-compiled version is provided 
for MS Windows. It can be installed from within the R environment on 
Windows systems.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-9-475-S4.zip]cc